An observational study in Renal Cell Carcinoma, sponsored by Ipsen. Completed at 91 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-15.
Sponsored by Ipsen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Carcinoma, Renal Cell by Ipsen — none open to participants now, 2 under way, none of them phase 3. Carcinoma, Renal Cell · Ipsen.
Among the 16 studies in Carcinoma, Renal Cell by Ipsen, this one is the 2nd largest by enrollment of the 13 observational ones that give a count, is one of 4 that started in 2018, is one of 13 observational ones, and was the 2nd registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.
Browse Carcinoma, Renal Cell studies →None of the 16 studies in Carcinoma, Renal Cell by Ipsen is open now. The open studies under Carcinoma, Renal Cell, anywhere →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 689 is above the median of 151 across 337 observational studies indexed under Carcinoma, Renal Cell.
Median enrollment 164 across the 2 interventional studies, 252 across the 13 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
2 of the studies in Carcinoma, Renal Cell by Ipsen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04106349IpsenObservational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC) | 2027-03-31 |
| NCT03647878IpsenStudy of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Carcinoma, Renal Cell by Ipsen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to adverse events (AEs) when used as a second line therapy or third and later line therapy. Other patterns of use of cabozantinib will also be described.
The study will follow the real-life management of patients in clinical practice. Visits will take place according to the study site's clinical practice. Cabozantinib is to be administered as directed by the investigator according to the study site's usual clinical practice and the Cabometyx™ Summary of Product Characteristics (SmPC).
Subjects with advanced RCC following prior VEGF-targeted therapy in real life settings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Data collection
Other: Data collection
Data collection
Other: Data collection
Only available evaluations as decided by the investigator based on local clinical practice will be collected.
This study also gives Cabozantinib. No intervention listed here names it: that was found by reading the record.
The proportion of subjects with dose modifications due to AEs
Time frame: 12 months
Reason for cabozantinib dose modification (any modification, reduction, temporary interruption or discontinuation)
Percentage of subjects with the following reasons - Disease progression, Adverse event, Subject non-compliance, Treatment resumed or re escalated, Subject decision, Clinical / investigator decision, Other
Time frame: 12 months
Description of number of cabozantinib dose modifications (any modification, reduction, temporary interruption, increase or discontinuation)
Time frame: 12 months
Median time to first cabozantinib dose modification (any modification, reduction, temporary interruption, increase or discontinuation) due to AEs and for any reason
Time frame: 12 months
Description of cabozantinib starting dose (combination of dose per intake and frequency)
Time frame: 12 months
Description of daily dose of cabozantinib received
Time frame: 12 months
Description of cabozantinib dose intensity (average daily dose compared to starting dose)
Time frame: 12 months
Duration of cabozantinib treatment (expressed as mean and median time to end of treatment)
Time frame: 12 months
Proportion of subjects with concomitant radiotherapies
Time frame: 12 months
Description of systemic therapy (drug name) planned following cabozantinib discontinuation
Percentage of subjects treated with the following drugs: Sunitinib, Pazopanib, Axitinib, Sorafenib, Bevacizumab, Cytokines, Everolimus, Lenvatinib, Nivolumab, Tivozanib, Experimental trial drug, Other, Unknown)
Time frame: 12 months
Overall best response
Per investigator assessment
Time frame: 12 months
Median Progression Free Survival (PFS) time
Defined as the time between the start date of cabozantinib and the date of progression or death. Clinical and radiographic (assessed by the investigator based on RECIST 1.1)
Time frame: 12 months
Overall Survival (OS) rate at the end of the study
Time frame: 12 months
Health care resource utilisation: number of visits to health care professionals (hospitalisation, surgical procedure, emergency room, physician, homecare by nurse) associated with the management of treatment-related AEs
Time frame: 12 months
Health care resource utilisation: Description of concomitant medications (by drug class and preferred name) associated with the management of treatment-related AEs
Time frame: 12 months
Health care resource utilisation: Description of number of unplanned laboratory tests associated with the management of treatment-related AEs
Time frame: 12 months
Incidence of all treatment-emergent non-serious and serious AEs
Time frame: 12 months
Ran from Apr 2018 to primary completion in May 2022, 48 months.
Of 42 industry-sponsored observational studies under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 91. This study's 48 months is close to that.
Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.